Tempus AI, Inc.

Tempus AI operates a healthcare technology platform that integrates clinical diagnostic capabilities with data analytics and a repository of multimodal patient data. The company's core offering is a closed-loop system connecting clinician workflows with laboratory testing, molecular diagnostics, and AI-powered insights. The platform supports next-generation sequencing (NGS) diagnostics, PCR profiling, anatomic and molecular pathology testing, and large-panel solid tumor and hematologic assays through its primary clinical assays (xT and xR), which analyze DNA, RNA transcriptome data, and incidental germline findings from blood or saliva samples.

Beyond core diagnostics, Tempus AI provides several specialized testing and software products. These include Hub, a clinical application for ordering and managing NGS tests; Lens, a research application for life sciences organizations; genetic testing focused on inherited conditions; nP, a pharmacogenomic assay for psychiatric patients; and Insights, a licensed library of de-identified clinical and molecular data. The company also offers clinical trial matching services, tumor-derived organoid modeling capabilities, and algorithm-based diagnostic applications.

Tempus AI maintains strategic collaborations with pharmaceutical companies including AstraZeneca, GlaxoSmithKline, and Recursion Pharmaceuticals. The company, incorporated in Nevada and headquartered in Chicago, operates with approximately 3,800 full-time employees and generates revenue primarily through diagnostics services, software licensing, and research partnerships. The company was formerly known as Tempus Labs, Inc. before rebranding in January 2023.